American Family Physician - ARBs vs. ACE inhibitors in patients with cardiac disease
NEW ORLEANS, LA, Nov 15, 2000
Most Popular
Eight Major Job Trends For 2008
3 Questions No Job Seeker Ever Wants To Be Asked?
Today’s Best Part-Time Jobs
Five Ways To Successfully Negotiate A Salary
5 Regular Mistakes In Public Speaking
On the basis of new data from the largest clinical study of its kind, Novartis is to seek worldwide approvals for its selective angiotensin II receptor blocker (ARB) Diovan(R) (valsartan) in the treatment of heart failure. Presented at the American Heart Association meeting today, the new data from the Valsartan Heart Failure Trial (Val-HeFT) show that Diovan significantly reduced combined all-cause mortality and morbidity in patients with heart failure also taking usual therapy. Diovan is now the only angiotensin II receptor blocker (ARB) to …
Read the rest of this article with a Free Trial at HighBeam Research.
